Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

521

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

521 results for “Patient survival”

Learn how ShareScore rates datasets ↗
geo16/100

Methylome analysis for prediction of long and short survival in glioblastoma patients from the Nordic phase 3 trial

GEO Series GSE207426. Homo sapiens. 59 samples. Type: Methylation profiling by array.

openGEO-OpenAug 2022View details →
geo16/100

Stratification of renal cell carcinoma patients by abundance of sarcomatoid features reveals differences in survival and underlying pathobiology

GEO Series GSE261172. Homo sapiens. 45 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2025View details →
geo16/100

Microarray CGH Profiling Of Serous Ovarian Tumours Identifies Novel Copy Number Alterations Associated with Patient Survival

GEO Series GSE29503. Homo sapiens. 164 samples. Type: Genome variation profiling by genome tiling array.

openGEO-OpenJun 2012View details →
geo16/100

Tissue-resident FOLR2+ macrophages associate with tumor-infiltrating CD8+ T cells and with increased survival of breast cancer patients

GEO Series GSE192935. Homo sapiens; Mus musculus. 58 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJan 2022View details →
geo12/100

Genomic profiles and survival prognosticators in African-American patients with acute myeloid leukemia

GEO Series GSE266099. Homo sapiens. 78 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMay 2024View details →
geo12/100

A mosaic renal myeloid subtype linked to immune escape correlates with poor patient survival in clear cell renal cell carcinoma [in vitro]

GEO Series GSE108311. Homo sapiens. 9 samples. Type: Expression profiling by array.

openGEO-OpenDec 2019View details →
geo12/100

Effects of altered expression and activity levels of casein kinase 1δ and ε on tumor growth and survival of colorectal cancer patients

GEO Series GSE57840. Homo sapiens. 12 samples. Type: Expression profiling by array.

openGEO-OpenMay 2017View details →
geo12/100

A mosaic renal myeloid subtype linked to immune escape correlates with poor patient survival in clear cell renal cell carcinoma

GEO Series GSE108312. Homo sapiens. 27 samples. Type: Expression profiling by array.

openGEO-OpenDec 2019View details →
geo12/100

A mosaic renal myeloid subtype linked to immune escape correlates with poor patient survival in clear cell renal cell carcinoma [ex vivo]

GEO Series GSE108310. Homo sapiens. 18 samples. Type: Expression profiling by array.

openGEO-OpenDec 2019View details →
geo12/100

The levels of human PDAC microRNAs’ expression in 10 patients with longest survival and 10 with shortest survival were selected

GEO Series GSE106198. Homo sapiens. 20 samples. Type: Non-coding RNA profiling by array.

openGEO-OpenOct 2020View details →
geo12/100

A β-catenin-regulated RNA processing transcriptional program imposes chemotherapy resistance and predicts T-ALL patient survival associated with high BRCA1 levels [ChIP-Seq]

GEO Series GSE180650. Homo sapiens. 29 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenDec 2022View details →
zenodo12/100

Dataset related to article "Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy."

<p>PURPOSE:</p> <p>This study evaluated patients, treatment, or disease characteristics that could predict response to stereotactic body radiation therapy (SBRT) and survival in a database of patients with oligometastatic disease from different solid tumors.</p> <p>METHODS AND MATERIALS:</p> <p>Patients treated with SBRT for oligometastatic disease between 2014 and 2015 were included. Patients were defined as oligometastatic if they were affected by a maximum of 5 active lesions in 3 different sites. They had to be treated with SBRT with radical intent.</p> <p>RESULTS:</p> <p>The study included 358 patients. With a median follow-up of 31.83&nbsp;months, local control at 6 and 24&nbsp;months was 94.6% and 78.9%, respectively. Distant progression was recorded in 279 patients (77.9%). Progression-free survival at 6 and 24&nbsp;months was 66.1% and 18.4%, respectively. At last follow-up, 195 patients (54.5%) were still alive in 59 cases with no evidence of disease. The median overall survival (OS) was 34.7&nbsp;months (95% confidence interval, 29.66-43.83). OS at 6 and 24&nbsp;months was 96.07% and 63.57%, respectively. On multivariable analysis, the presence of lung metastases (hazard ratio [HR], 0.50 [0.33-0.75]; P&nbsp;=&nbsp;.001) and nodal metastases (HR, 0.44 [0.24-0.78]; P&nbsp;=&nbsp;.005) was related to longer OS. Primary lung cancer (HR, 1.89 [1.14-3.13]; P&nbsp;=&nbsp;.013), increasing age (HR, 1.02 [1.01-1.04]; P&nbsp;=&nbsp;.002), and the presence of metastatic sites other than the irradiated ones (HR, 2.19 [1.39-3.43]; P&nbsp;=&nbsp;.001) were all independent predictors of shorter OS. Local response was associated with OS.</p> <p>CONCLUSIONS:</p> <p>SBRT for patients with oligometastatic disease is effective. Local response is strongly correlated with patients&#39;&#39; prognosis, also underlying its relevance in a metastatic setting.</p>

restrictedMar 2020View details →
zenodo12/100

Cancer-specific Survival of Uveal Melanoma Patients by Diagnosis Era (A, C, D, E) and Tumor Stage (B, F,G,H)

<p>Cancer-specific Survival of Uveal Melanoma Patients by Diagnosis Era (A, C, D, E) and Tumor Stage (B, F,G,H)</p>

restrictedJul 2020View details →
zenodo12/100

Data set from Mazzaccaro D, Modafferi A, Malacrida G, Nano G. Assessment of long-term survival and stroke after carotid endarterectomy and carotid stenting in patients older than 80 years. J Vasc Surg. 2019 Aug;70(2):522-529. doi: 10.1016/j.jvs.2018.10.121. Epub 2019 Mar 2. PMID: 30837178.

<p>Data set from Mazzaccaro D, Modafferi A, Malacrida G, Nano G. Assessment of long-term survival and stroke after carotid endarterectomy and carotid stenting in patients older than 80 years. J Vasc Surg. 2019 Aug;70(2):522-529. doi: 10.1016/j.jvs.2018.10.121. Epub 2019 Mar 2. PMID: 30837178.</p> <p>&nbsp;</p> <p>This is the abstract:</p> <p><strong>Objective: </strong> The objective of this study was to analyze preoperative risk factors affecting long-term survival and the occurrence of stroke in patients older than 80 years undergoing either carotid endarterectomy (CEA) or carotid artery stenting (CAS) for carotid stenosis.</p> <p><strong>Methods: </strong> Data of all consecutive patients treated from January 1999 to December 2017 were retrospectively reviewed and outcomes analyzed. Kaplan-Meier analysis was used to estimate long-term survival and the risk of stroke for both groups. Cox proportional hazards analysis was used to assess the relative risk of all-cause mortality and long-term stroke for patients in the presence of selected comorbidities, including preoperative symptoms, coronary artery disease, chronic renal failure, atrial fibrillation (AF), hypertension, diabetes mellitus, and dyslipidemia. A P value &lt;.05 was considered statistically significant.</p> <p><strong>Results: </strong> A total of 473 patients older than 80 years (298 men [63%]) underwent either CEA (n = 178) or CAS. At 30 days, one patient died in the CEA group of unrelated causes; no deaths were recorded after CAS (0.6% vs 0%; P = .18). At 5 years, survival was 67.6% &plusmn; 4.9% after CEA and 90.2% &plusmn; 2.3% after CAS (P &lt; .0001). The main cause of death after CEA and CAS was a neoplasm. Estimated freedom from any stroke at 5 years was 97.3% &plusmn; 0.5% after CEA and 93.2% &plusmn; 1.2% after CAS (P = .07). The presence of preoperative AF significantly affected long-term mortality after CAS (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.34-1.98; P = .04) as well as being classified as American Society of Anesthesiologists class 3 at evaluation of the preoperative anesthesiology risk. The presence of preoperative AF was the only factor that significantly affected the occurrence of long-term stroke after both CAS (HR, 2.28; 95% CI, 1.86-5.63; P = .001) and CEA (HR, 3.45; 95% CI, 2.29-8.19; P = .005).</p> <p><strong>Conclusions: </strong> Both CEA and CAS showed low 30-day mortality and any-stroke rates in patients older than 80 years. In the long term, survival was significantly better after CAS; however, deaths after CEA and CAS were mainly unrelated to the procedure. No significant differences were recorded in the occurrence of any stroke in the long term. The presence of preoperative AF significantly affected long-term survival after CAS as well as being classified as American Society of Anesthesiologists class 3 at evaluation of the preoperative anesthesiology risk. The presence of preoperative AF also significantly affected long-term risk of stroke after both CAS and CEA.</p> <p>&nbsp;</p>

restrictedOct 2020View details →
zenodo12/100

Dataset related to article "Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR)"

<p>This record contains raw data related to article "Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR)"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Delivering stereotactic ablative radiotherapy (SABR) in patients with multiple oligometastases represents a challenge for clinical and technical reasons. We aimed to evaluate the outcome of patients affected by multiple oligometastases treated with SABR and the impact of tumor volume on survival.</p><p><strong>Materials and methods: </strong>We included all the patients treated with single course SABR for 3 to 5 extracranial oligometastases. All patients were treated with the volumetric modulated arc therapy (VMAT) technique with ablative intent. End-points of the analysis were overall survival (OS), progression free survival (PFS), local control (LC) and toxicity.</p><p><strong>Results: </strong>136 patients were treated from 2012 to 2020 on 451 oligometastases. Most common primary tumor was colorectal cancer (44.1%) followed by lung cancer (11.8%). A total of 3, 4 and 5 lesions were simultaneously treated in 102 (75.0%), 26 (19.1%), and 8 (5.9%) patients, respectively. Median total tumor volume (TTV) was 19.1 cc (range 0.6-245.1). With a median follow-up of 25.0 months, OS at 1 and 3 years was 88.4% and 50.2%, respectively. Increasing TTV was independent predictive factor of worse OS (HR 2.37, 95% CI 1.18-4.78, p = 0.014) and PFS (HR 1.63, 95% CI 1.05-2.54; p = 0.028). Median OS was 80.6 months if tumor volume was ≤ 10 cc (1 and 3 years OS rate 93.6% and 77.5%, respectively), and 31.1 months if TTV was higher than 10 cc (1 and 3 years OS rate 86.7% and 42.3%, respectively). Rates of LC at 1 and 3 years were 89.3% and 76.5%. In terms of toxicity, no grade 3 or higher toxicity was reported both in the acute and late settings.</p><p><strong>Conclusion: </strong>We demonstrated the impact of tumor volume on survival and disease control of patients affected by multiple oligometastases treated with single course SABR</p>

restrictedNov 2023View details →
zenodo12/100

Dataset related to article "Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization"

<p>This record contains raw data related to article "Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization"</p><p>&nbsp;<strong>Abstract</strong></p><p>Alterations in nutritional status, in particular sarcopenia, have been extensively associated with a poor prognosis in cirrhotic patients regardless of the etiology of liver disease. Less is known about the predictive value of myosteatosis, defined as pathological fat infiltration into the skeletal muscle. We retrospectively analyzed a cohort of 151 cirrhotic patients with unresectable hepatocellular carcinoma (HCC) who underwent their first trans-arterial embolization (TAE) between 1 March 2011 and 1 July 2019 at our Institution. Clinical and biochemical data were collected. Sarcopenia was assessed using the L3-SMI method while myosteatosis with a dedicated segmentation suite (3D Slicer), using a single slice at an axial plane located at L3 and calculating the IMAC (Intramuscular Adipose Tissue Content Index). The sex-specific cut-off values for defining myosteatosis were IMAC &gt; −0.44 in males and &gt;−0.31 in females. In our cohort, 115 (76%) patients were included in the myosteatosis group; 128 (85%) patients had a coexistent diagnosis of sarcopenia. Patients with myosteatosis were significantly older and showed higher BMI than patients without myosteatosis. In addition, male gender and alcoholic- or metabolic-related cirrhosis were most represented in the myosteatosis group. Myosteatosis was not associated with a different HCC burden, length of hospitalization, complication rate, and readmission in the first 30 days after discharge. Overall survival was not influenced by the presence of myosteatosis</p>

restrictedNov 2023View details →
zenodo12/100

Dataset related to article "Impact of active cancer on COVID-19 survival: a matchedanalysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy"

<p>This record contains raw data related to article &quot;Impact of active cancer on COVID-19 survival: a matchedanalysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy&quot;</p> <p><strong>Background: </strong> The impact of active cancer in COVID-19 patients is poorly defined; however, most studies showed a poorer outcome in cancer patients compared to the general population.</p> <p><strong>Methods: </strong> We analysed clinical data from 557 consecutive COVID-19 patients. Uni-multivariable analysis was performed to identify prognostic factors of COVID-19 survival; propensity score matching was used to estimate the impact of cancer.</p> <p><strong>Results: </strong> Of 557 consecutive COVID-19 patients, 46 had active cancer (8%). Comorbidities included diabetes (n = 137, 25%), hypertension (n = 284, 51%), coronary artery disease (n = 114, 20%) and dyslipidaemia (n = 122, 22%). Oncologic patients were older (mean age 71 vs 65, p = 0.012), more often smokers (20% vs 8%, p = 0.009), with higher neutrophil-to-lymphocyte ratio (13.3 vs 8.2, p = 0.046). Fatality rate was 50% (CI 95%: 34.9;65.1) in cancer patients and 20.2% (CI 95%: 16.8;23.9) in the non-oncologic population. Multivariable analysis showed active cancer (HR<sub>active</sub>: 2.26, p = 0.001), age (HR<sub>age&gt;65years</sub>: 1.08, p &lt; 0.001), as well as lactate dehydrogenase (HR<sub>LDH&gt;248mU/mL</sub>: 2.42, p = 0.007), PaO2/FiO2 (HR<sub>continuous</sub>: 1.00, p &lt; 0.001), procalcitonin (HR<sub>PCT&gt;0.5ng/mL</sub>: 2.21, p &lt; 0.001), coronary artery disease (HR<sub>yes</sub>: 1.67, p = 0.010), cigarette smoking (HR<sub>yes</sub>: 1.65, p = 0.041) to be independent statistically significant predictors of outcome. Propensity score matching showed a 1.92&times; risk of death in active cancer patients compared to non-oncologic patients (p = 0.013), adjusted for ICU-related bias. We observed a median OS of 14 days for cancer patients vs 35 days for other patients.</p> <p><strong>Conclusion: </strong> A near-doubled death rate between cancer and non-cancer COVID-19 patients was reported. Active cancer has a negative impact on clinical outcome regardless of pre-existing clinical comorbidities.</p>

restrictedJan 2022View details →
zenodo12/100

Impact of Wide Local Excision on Melanoma Patient Survival: A Population-Based Study

<p>Promoting standardization and quality assurance (QA) in oncology on the strength of real-world data is essential to ensure better patient outcomes. Wide excision after primary tumor biopsy is a fundamental step in the therapeutic pathway for cutaneous malignant melanoma (CMM). The aim of this population-based cohort study is to assess adherence to wide local excision in a cohort of patients diagnosed with CMM and the impact of this recommended procedure on overall and disease-specific survival.This retrospective cohort study concerns CMM patients diagnosed in the Veneto region (north-east Italy) in 2017, included in the high-resolution Veneto Cancer Registry, and followed up through linkage with the regional mortality registry up until February 29th, 2020. Using population-level real-world data, linking patient-level cancer registry data with administrative records of clinical procedures may shed light on the real-world treatment of CMM patients in accordance with current guidelines. After excluding TNM stage IV patients, a Cox regression analysis was performed to test whether the completion of a wide local excision was associated with a difference in melanoma-specific and overall survival, after adjusting for other covariates. No wide excision after the initial biopsy was performed in 9.7% of cases in our cohort of 1,305 patients. After adjusting for other clinical prognostic characteristics, Cox regression revealed that failure to perform a wide local excision raised the hazard ratio of death in terms of overall survival (HR = 4.80, 95% CI: 2.05-11.22,&nbsp;<em>p</em>&nbsp;&lt; 0.001) and melanoma-specific survival (HR = 2.84, 95% CI: 1.04-7.76,&nbsp;<em>p</em>&nbsp;= 0.042). By combining clinical and administrative data, this study on real-world clinical practice showed that almost one in ten CMM patients did not undergo wide local excision surgery. Monitoring how diagnostic-therapeutic protocols are actually implemented in the real world may contribute significantly to promoting quality improvements in the management of oncological patients.</p>

restrictedMar 2022View details →
zenodo12/100

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV itolizumab Trial: RESURRECT

<p>Datasets pertaining to the manuscript,&nbsp;Original Research, entitled &ldquo;<strong>RE</strong>covery and <strong>SUR</strong>vival of patients with moderate to severe acute <strong>RE</strong>spiratory distress syndrome (ARDS) due to <strong>C</strong>OVID-19: a multicentre, single-arm, Phase IV Itolizumab <strong>T</strong>rial: <strong>RESURRECT</strong>&rdquo; are submitted here.&nbsp;&nbsp;</p>

restrictedDec 2022View details →
zenodo12/100

TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study

<p><strong>PURPOSE</strong> Bevacizumab (BEV) is considered an effective treatment option for advanced ovarian carcinoma. However, to date, there are no biomarkers that define a BEV-responsive patient subpopulation.</p> <p><strong>METHODS</strong> In the context of the MITO16A/MaNGO OV-2 trial, a phase IV study of chemotherapy combined with BEV in first-line treatment of advanced ovarian carcinoma, we evaluated <em>TP53</em> mutations by next generation sequencing (NGS) and p53 protein expression by immunohistochemistry (IHC) on 202 and 311 cases, respectively. We further correlated NGS and IHC data with clinicopathological characteristics and survival of patients.</p> <p><strong>RESULTS</strong> <em>TP53</em> mutations of unknown function (named unclassified), mostly of the missense type, represented the majority of variants in our population (44.4%) and were associated with a significantly improved overall survival both in univariate (p=0.03, HR=0.43) and multivariate analysis (p=0.012, HR=0.39). Concordance between <em>TP53 </em>mutational analysis and protein expression was 91%. A trend toward improved OS was observed in patients with p53 IHC overexpression (HR=0.70, p=0.15) compared to p53 wild-type patients.</p> <p><strong>CONCLUSION </strong>Our results indicate that the presence of unclassified <em>TP53</em> mutations has favorable prognostic significance in patients with ovarian carcinoma receiving upfront BEV plus chemotherapy. In particular, unclassified missense <em>TP53</em> mutations characterize a subpopulation of patients with a significant survival advantage, independently of clinicopathological characteristics. Our findings warrant future investigations to confirm the prognostic impact of <em>TP53 </em>mutations in BEV-treated ovarian carcinoma patients and deserve to be assessed for their potential predictive role in future randomized clinical studies.</p>

restrictedOct 2023View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.